

Major R&D Pipeline (Oncology)

As of Oct 2018



	Generic Name/Project Code Number (Class)	Target indication	Region	Stage			
				Phase 1	Phase 2	Phase 3	NDA/BLA
ADC Franchise	DS-8201 (Anti-HER2 ADC)	mBC (HER2 positive post T-DM1)	JP/US/EU/Asia				
		mBC (HER2 positive vs. T-DM1)	JP/US/EU/Asia				
		mGC (HER2 positive post trastuzumab)	JP/Asia				
		CRC	JP/US/EU				
		NSCLC	JP/US/EU				
		mBC and bladder cancer (w nivolumab)	US/EU				
	U3-1402 (Anti-HER3 ADC)	mBC	JP/US				
		NSCLC	US				
DS-1062 (Anti-TROP-2 ADC)	NSCLC	JP/US					
AML Franchise	Quizartinib/AC220 (FLT3 inhibitor)	AML (Relapsed/Refractory)	JP/US/EU/Asia				
		AML (1 st line)	JP/US/EU/Asia				
	DS-3032 (MDM2 inhibitor)	Solid tumor	JP/US				
		AML	US				
	DS-3201 (EZH1/2 inhibitor)	ATL/L, PTCL	JP				
		AML, ALL	US				
	PLX51107 (BRD4 inhibitor)	AML, solid tumor	US				
	DS-1001 (IDH1m inhibitor)	Glioma	JP				
PLX2853 (BRD4 inhibitor)	AML, solid tumor	US					
Breakthrough Science	Pexidartinib (CSF-1/KIT/FLT3 inhibitor)	TGCT	US/EU				
	DS-1647 (G47Δ virus)	Glioblastoma	JP				
	Axi-Cel® (Anti-CD19 CAR-T cells)	BCL	JP				
	DS-1205 (AXL inhibitor)	NSCLC (w osimertinib(US), gefitinib (JP))	US/JP				

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B-cell lymphoma, CRC: colorectal cancer, mBC: metastatic breast cancer, mGC: metastatic gastric cancer, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma, TGCT: tenosynovial giant cell tumor

★: projects in the field of oncology which are planned for application based on the results of P2 studies

Major R&D Pipeline (SM/Vaccine) As of Oct 2018

	Generic Name/Project Code Number (Class)	Target Indication	Region	Stage			
				Phase 1	Phase 2	Phase 3	NDA
Specialty medicine (SM)	Edoxaban/DU-176b (Fxa inhibitor)	AF	ASCA	▶			
		VTE	ASCA	▶			
		Very elderly patients AF	JP	▶			
	Prasugrel/CS-747 (anti-platelet agent)	Ischemic stroke	JP	▶			
	Esaxerenone/CS-3150 (MR antagonist)	Hypertension	JP	▶			
		Diabetic nephropathy	JP	▶			
	DS-1040 (TAFIa inhibitor)	Acute ischemic stroke, Acute pulmonary embolism	JP/US/EU	▶			
	DS-2330 (hyperphosphatemia treatment)	Hyperphosphatemia in chronic kidney disease	-	▶			
	Mirogabalin/DS-5565 ($\alpha 2\delta$ ligand)	DPNP, PHN	JP	▶			
	Laninamivir/CS-8958 (neuraminidase inhibitor)	Influenza	JP	▶			
	DS-5141 (ENA oligonucleotide)	DMD	JP	▶			
DS-1211(TNAP inhibitor)	Prevention of ectopic calcification diseases	US	▶				
Vaccine	VN-0107/MEDI3250 (live attenuated influenza vaccine)	Prevention of seasonal influenza	JP	▶			
	VN-0105 (DPT-IPV/Hib)	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	▶			
	VN-0102/JVC-001 (Measles-Mumps-Rubella vaccine)	Prevention of Measles, Mumps and Rubella	JP	▶			

AF: atrial fibrillation, DMD: Duchenne muscular dystrophy, DPNP: diabetic peripheral neuropathic pain, PHN: Postherpetic neuralgia, VTE: venous thromboembolism